Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | An insight into novel measures being explored for the diagnosis of cardiac amyloidosis

Faizi Jamal • 28 May 2024
ISA 2024
Amyloidosis Rare Diseases

Faizi Jamal, MD, City of Hope, Duarte, CA, discusses the novel measures being explored for the diagnosis of cardiac amyloidosis. In nuclear medicine, work is being conducted to identify radioisotopes specific to amyloid proteins such as light chain (AL) or transthyretin (TTR). Cardiac MRI may become an increasingly useful diagnostic tool in cardiac amyloidosis, using late gadolinium enhancement (LGE), extracellular volume (ECV), T1, and T2 as measures of function. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research supported by an award from Johnson & Johnson Innovation, LLC.

More from Faizi Jamal

Fostering a multidisciplinary approach to treating amyloidosis
0:56
Fostering a multidisciplinary approach to treating amyloidosis
Faizi Jamal • 28 May 2024
Diagnostic utility of left atrial and right ventricular strain analyses in AL amyloidosis
3:02
Diagnostic utility of left atrial and right ventricular strain analyses in AL amyloidosis
Faizi Jamal • 28 May 2024

Related Videos

Bezuclastinib in advanced systemic mastocytosis: the APEX trial
2:34
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
Daniel DeAngelo • 11 Jun 2026
Advances in the clinical understanding of advanced SM and educational gaps that remain
1:17
Advances in the clinical understanding of advanced SM and educational gaps that remain
Deepti Radia • 12 Jun 2026
Updates with bezuclastinib in non-advanced and advanced systemic mastocytosis: SUMMIT & APEX trials
2:41
Updates with bezuclastinib in non-advanced and advanced systemic mastocytosis: SUMMIT & APEX trials
Deepti Radia • 12 Jun 2026
Advances in BPDCN research: novel agents, combination approaches & increased disease awareness
2:50
Advances in BPDCN research: novel agents, combination approaches & increased disease awareness
Naveen Pemmaraju • 12 Jun 2026
The content of VJHemOnc is intended for healthcare professionals